Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism
Status:
Completed
Trial end date:
1999-12-13
Target enrollment:
Participant gender:
Summary
The primary objective was to assess the safety and tolerability of cinacalcet in adults with
primary hyperparathyroidism (HPT) when administered as a single oral once daily doses for 6
consecutive weeks and twice daily for 15 consecutive days.